Hangzhou Tigermed Consulting Co., Ltd (HKG: 3347)
Hong Kong
· Delayed Price · Currency is HKD
29.55
-0.60 (-1.99%)
Jan 3, 2025, 2:24 PM HKT
Hangzhou Tigermed Consulting Revenue
Hangzhou Tigermed Consulting had revenue of 1.71B CNY in the quarter ending September 30, 2024, a decrease of -11.87%. This brings the company's revenue in the last twelve months to 6.80B, down -7.21% year-over-year. In the year 2023, Hangzhou Tigermed Consulting had annual revenue of 7.38B with 4.21% growth.
Revenue (ttm)
6.80B CNY
Revenue Growth
-7.21%
P/S Ratio
n/a
Revenue / Employee
701.08K CNY
Employees
9,701
Market Cap
45.28B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.38B | 298.57M | 4.21% |
Jan 1, 2023 | 7.09B | 1.87B | 35.91% |
Jan 1, 2022 | 5.21B | 2.02B | 63.32% |
Dec 31, 2020 | 3.19B | 388.97M | 13.88% |
Dec 31, 2019 | 2.80B | 502.65M | 21.85% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeiGene | 26.04B |
Hansoh Pharmaceutical Group Company | 13.00B |
JD Health International | 58.84B |
WuXi Biologics | 18.39B |
Sinopharm Group | 634.32B |
Innovent Biologics | 8.01B |
Sino Biopharmaceutical | 29.86B |
CSPC Pharmaceutical Group | 33.53B |